Furthermore, recent studies in other cancers have shown that increased systemic and tumor-associated IL-8 levels correlate with reduced clinical benefits of ICB therapies used in advanced melanoma, NSCLC, urothelial carcinoma, renal cell carcinoma, and glioma [210,211,212,213]. This evidence concerns the gene CXCL8 and neoplasm.